← Leaderboards
Clive Ballard
University Of Southern California
$1,923,359
Attributed
$3,846,717
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2019–23$2M$1.5M$1M$500K$0
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$3,846,717 · 1
By mechanism
R01$3,846,717 · 1
Top collaborators
- Lon S Schneider6 shared
Most similar at University Of Southern California
Same institution · by research overlap
- Lon S Schneider$40,841,066
- Matthew Robert Pratt$5,834,380
- Qilong Ying$7,741,658
- Song Guo Zheng$4,339,917
Others in their field
Other Emerging Leaders on “Alzheimer&Apos”
- Lance Allen Johnson · University Of Kentucky$7,508,882
- Hyacinth Idu Hyacinth · University Of Cincinnati$6,781,590
- Yi Su · Weill Medical Coll Of Cornell Univ$6,486,733
- Julia Tcw · Icahn School Of Medicine At Mount Sinai$6,079,215
- Jessica Brooke Langbaum · Banner Health$6,050,741
- Timothy Yikai Huang · Sanford Burnham Prebys Medical Discovery Institute$5,936,362
Research focus
Alzheimer&AposAdverse EventBcl2 GeneCellsAlzheimerâS Disease BiomarkerAge-Associated Memory ImpairmentAnatomyAgingAnoxiaApoptosisAstrocytesAutophagocytosisAmericanBax GeneAffectBiochemicalAnimalsBiological MarkersClinical DevelopmentBrainCasp3 GeneCell DeathCell PhysiologyClinically Relevant
Grant awards (6)
(-)-Phenserine inhibition of neuronal death in Alzheimerâs disease and developing brain-labeled plasma exosomes assays as biomarkers for a phenserine phase 1b ascending dose trial$714,437
R01 · FY2023 · AG
(-)-Phenserine inhibition of neuronal death in Alzheimerâs disease and developing brain-labeled plasma exosomes assays as biomarkers for a phenserine phase 1b ascending dose trial$684,780
R01 · FY2022 · AG
(-)-Phenserine inhibition of neuronal death in Alzheimerâs disease and developing brain-labeled plasma exosomes assays as biomarkers for a phenserine phase 1b ascending dose trial$695,025
R01 · FY2021 · AG
(-)-Phenserine inhibition of neuronal death in Alzheimer's disease and developing brain-labeled plasma exosomes assays as biomarkers for a phenserine phase 1b ascending dose trial$702,380
R01 · FY2020 · AG
(-)-Phenserine inhibition of neuronal death in Alzheimerâs disease and developing brain-labeled plasma exosomes assays as biomarkers for a phenserine phase 1b ascending dose trial$725,263
R01 · FY2019 · AG
(-)-Phenserine inhibition of neuronal death in Alzheimerâs disease and developing brain-labeled plasma exosomes assays as biomarkers for a phenserine phase 1b ascending dose trial$324,832
R01 · FY2019 · AG